People | July 31, 2025
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
